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Endocrine therapy with selective oestrogen receptor
modulators (SERMs), such as tamoxifen, or agents
leading to oestrogen deprivation, gonadotrophin-
releasing hormone (GnRH) agonists in premenopausal
and aromatase inhibitors in postmenopausal women, are
widely used in the treatment of all stages of breast cancer.
Resistance to such treatments canbe intrinsic andoccur at
ﬁrst exposure or acquired after initial response. The
identiﬁcation of predictors of resistance to these agents is
important for the appropriate selection of patients for
treatment. Additionally, where these predictors are me-
chanistically involved in the resistance, their identiﬁcation
is important for the development and application of new
agents targeted at the pathways involved.
It has become increasingly clear that only those pa-
tients that present as positive for oestrogen receptor
(ER)-a and/or progesterone receptor (PgR) beneﬁt from
hormonal therapy of any sort. The small fraction of
patients that are ER-PgR+ (<5% of total in almost all
reports) is important to deﬁne as they do show beneﬁt,
despite having no measurable ER. Some data indicate
that ER-b expression may be associated with a poorer
likelihood of response to endocrine therapy, but the
data are not suﬃciently compelling to assess this marker
routinely [1]. Most patients continue to show ER+ dis-
ease at relapse during endocrine therapy, but approxi-
mately 15% of patients treated with tamoxifen show no
ER in relapsed lesions [2].
The growth factor receptors, HER2 and epidermal
growth factor receptor (EGFR), are less frequently
positive in ER+ breast cancers, but there is increas-
ingly strong evidence that tumours in which one or
both are co-expressed with ER show a reduced like-
lihood of beneﬁt from tamoxifen. This evidence comes
from a series of adjuvant studies of tamoxifen (none
of which is individually persuasive in this regard) and
2 neoadjuvant studies of tamoxifen versus an ar-
omatase inhibitor [3,4]. Of particular interest, ER+-
HER2/EGFR+ tumours showed a better response to
the aromatase inhibitors in these latter studies.
This may be due to cross-talk between the growth
factor receptor and ER signalling pathways that in
model systems leads to sensitisation of the ER to
oestrogen stimulation and to the agonist eﬀects of
tamoxifen [5].
PgR expression is thought to be highly dependent on
the classical mechanism of ER-oestrogen response ele-
ment signalling. There is recent evidence that theremay be
diﬀerential beneﬁt from aromatase inhibitors and ta-
moxifen according to the PgR status of ER tumours. A
retrospective subgroup analysis in the arimidex, tamoxi-
fen, alone or in combination (ATAC) adjuvant trial of
anastrozole versus tamoxifen versus the combination of
anastrozole and tamoxifen found that patients that were
ER+PgR+ or ER+PgR- had a similar recurrence-free
survival (RFS) on anastrozole, but that patients that were
ER+PgR- faired much worse on tamoxifen than the
ER+PgR+ patients. This resulted in a substantially
greater beneﬁt for anastrozole over tamoxifen in the
ER+PgR- than in the ER+PgR+ patients, although
greater beneﬁt over tamoxifen remained in the latter
group. There is signiﬁcant co-segregation of growth fac-
tor receptor-positivity with PgR-negativity. Therefore, it
may be growth factor receptor-positivity that is respon-
sible for this diﬀerential beneﬁt and PgR expression may
be a marker of this mechanism. This possibility will be
examined by growth factor receptor measurements in a
retrospective collection of excised tumours from the
ATAC trial in study TA/01 (also known as TransATAC).
Almost all studies of response and resistance in breast
cancer depend on clinical measurement of tumour
growth or regression and the linkage of this to putative
biochemical or molecular markers of response/resis-
tance. By such clinical measures, approximately 50% of
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ER+ patients may be deemed responsive or have long-
term stable disease with ﬁrst-line therapies. If, instead,
one examines the eﬀects on tumour cell proliferation
(the major determinant of tumour growth changes due
to hormonal therapy), it is clear that reduced prolifer-
ation, as measured by the nuclear marker Ki67, occurs
in approximately 90% of ER+ patients treated with
aromatase inhibitors and 80% with tamoxifen. Thus,
measurements with molecular markers indicate that the
great majority of ER+ breast cancers have some de-
pendence on oestrogen, but that this may be insuﬃcient
to lead to regression for many.
In summary, oestrogen antagonism and oestrogen
deprivation are major therapeutic strategies of known
beneﬁt in breast cancer. However, not all patients ben-
eﬁt from therapy and almost all that present with ad-
vanced disease relapse during therapy. The major
determinant of de novo resistance is ER-negativity.
While relapse is sometimes associated with the devel-
opment of ER-negative disease, in most patients ER
persists. Instead, growth factor receptors and their as-
sociated downstream pathways appear to be intimately
involved in the mechanisms of acquired resistance.
There is increasing evidence that the mechanisms of
resistance diﬀer, at least partially, between tamoxifen
and aromatase inhibitors.
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